Thorsten Braun1, Deborah M Sloboda2, Boris Tutschek3, Thomas Harder4, John R G Challis5, Joachim W Dudenhausen4, Andreas Plagemann4, Wolfgang Henrich4. 1. Departments of Obstetrics and Division of Experimental Obstetrics, Study Group Perinatal Programming, Charité Campus Virchow, Berlin, Germany. Electronic address: thorsten.braun@charite.de. 2. Departments of Biochemistry and Biomedical Sciences, Obstetrics and Gynecology and Pediatrics, McMaster University, Hamilton, ON, Canada. 3. Medical Faculty Heinrich Heine University, Düsseldorf, Germany. 4. Departments of Obstetrics and Division of Experimental Obstetrics, Study Group Perinatal Programming, Charité Campus Virchow, Berlin, Germany. 5. Department of Physiology, Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada; Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada; Departments of Obstetrics and Gynecology, University of Western Australia, Perth, WA, Australia.
Abstract
OBJECTIVE: To determine the effects of betamethasone on fetal growth and neonatal outcomes. METHODS: A retrospective cohort study was performed of deliveries that occurred at Charité University Hospital Berlin, Germany, between January 1996 and December 2008. The betamethasone group included women with preterm labor and symptomatic contractions, cervical insufficiency, preterm premature rupture of membranes, or vaginal bleeding. Women in the control group were matched for gestational age at time of delivery and had not received betamethasone. Fetal growth changes and neonatal anthropometry were compared. RESULTS: Among 1799 newborns in the betamethasone group and 42 240 in the control group, betamethasone was associated with significantly lower birth weight (154 g lower on average) after adjusting for confounders (e.g. hypertension, smoking, and maternal weight), sex, and gestational age at delivery (P<0.05). The higher the dose, the greater the difference in mean birth weight versus controls in births before 34(+0)weeks (≤16 mg -444 g; 24 mg -523 g; >24 mg -811 g), without a detectable improvement in neonatal morbidity or mortality. There was a dose-dependent decline in expected fetal weight gain as estimated by serial ultrasonography examinations 6-8 weeks after betamethasone administration (P<0.05). CONCLUSION: Betamethasone exposure reduces fetal weight gain in a dose-dependent manner without improving neonatal morbidity or mortality.
OBJECTIVE: To determine the effects of betamethasone on fetal growth and neonatal outcomes. METHODS: A retrospective cohort study was performed of deliveries that occurred at Charité University Hospital Berlin, Germany, between January 1996 and December 2008. The betamethasone group included women with preterm labor and symptomatic contractions, cervical insufficiency, preterm premature rupture of membranes, or vaginal bleeding. Women in the control group were matched for gestational age at time of delivery and had not received betamethasone. Fetal growth changes and neonatal anthropometry were compared. RESULTS: Among 1799 newborns in the betamethasone group and 42 240 in the control group, betamethasone was associated with significantly lower birth weight (154 g lower on average) after adjusting for confounders (e.g. hypertension, smoking, and maternal weight), sex, and gestational age at delivery (P<0.05). The higher the dose, the greater the difference in mean birth weight versus controls in births before 34(+0)weeks (≤16 mg -444 g; 24 mg -523 g; >24 mg -811 g), without a detectable improvement in neonatal morbidity or mortality. There was a dose-dependent decline in expected fetal weight gain as estimated by serial ultrasonography examinations 6-8 weeks after betamethasone administration (P<0.05). CONCLUSION:Betamethasone exposure reduces fetal weight gain in a dose-dependent manner without improving neonatal morbidity or mortality.
Authors: Elisabeth B Binder; Thorsten Braun; Sonja Entringer; Darina Czamara; Linda Dieckmann; Simone Röh; Sarah Kraemer; Rebecca C Rancourt; Sara Sammallahti; Eero Kajantie; Hannele Laivuori; Johan G Eriksson; Katri Räikkönen; Wolfgang Henrich; Andreas Plagemann Journal: Clin Epigenetics Date: 2021-08-26 Impact factor: 6.551
Authors: Augusto F Schmidt; Matthew W Kemp; Judith Rittenschober-Böhm; Paranthaman S Kannan; Haruo Usuda; Masatoshi Saito; Lucy Furfaro; Shimpei Watanabe; Sarah Stock; Boris W Kramer; John P Newnham; Suhas G Kallapur; Alan H Jobe Journal: Am J Obstet Gynecol Date: 2017-11-11 Impact factor: 8.661
Authors: Augusto F Schmidt; Paranthaman S Kannan; James P Bridges; Alyssa Filuta; Dakota Lipps; Matthew Kemp; Lisa A Miller; Suhas G Kallapur; Yan Xu; Jeffrey A Whitsett; Alan H Jobe Journal: Sci Rep Date: 2019-06-21 Impact factor: 4.379
Authors: Karen Klein; Elizabeth M McClure; Daniela Colaci; Vanessa Thorsten; Patricia L Hibberd; Fabian Esamai; Ana Garces; Archana Patel; Sarah Saleem; Omrana Pasha; Elwyn Chomba; Waldemar A Carlo; Nancy F Krebs; Shivaprasad Goudar; Richard J Derman; Edward A Liechty; Marion Koso-Thomas; Pierre M Buekens; José M Belizán; Robert L Goldenberg; Fernando Althabe Journal: Reprod Health Date: 2016-05-24 Impact factor: 3.223